article thumbnail

First biologic approved in Scotland for hidradenitis suppurativa since 2016

Drug Discovery World

It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The post First biologic approved in Scotland for hidradenitis suppurativa since 2016 appeared first on Drug Discovery World (DDW).

Licensing 162
article thumbnail

AI-driven drug company secures $372m Series D funding

Drug Discovery World

To address this bottleneck, Formation Bio (launched in 2016 as TrialSpark) has built technology platforms, processes, and capabilities with the aim of accelerating drug development and clinical trials. .” Advancements in AI are creating more candidate drugs than the industry can progress.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evotec and BMS enter drug discovery licence agreement

Drug Discovery World

Evotec and BMS originally entered their neurodegeneration partnership in 2016. A first programme, BMS-986419 or EVT8683, targeting eIF2b, was in-licensed by BMS in September 2021, following the successful filing of an IND application with the FDA and has proceeded into clinical Phase I trials.

Licensing 189
article thumbnail

Moderna sues Pfizer/BioNTech over Covid patent

Drug Discovery World

The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its mRNA technology filed between 2010 and 2016. They are related to the earlier cases of Moderna’s patented technologies which were clinically tested in 2015 and 2016.

Vaccine 130
article thumbnail

Merck and Moderna to jointly develop personalised cancer vaccine 

Drug Discovery World

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The Phase II trial is fully enrolled and primary data are expected in the fourth quarter of 2022. . “We

Vaccine 130
article thumbnail

Why have medicines progressed so little in the last decades?

Drug Discovery World

5 Reliability of animal testing Even the few drugs that go on to be licensed for use in the general population can have unexpected and serious adverse effects once they are prescribed in large numbers. link] Development Success Rates 2006-2015 – BIO, Biomedtracker, Amplion 2016.pdf ATLA Altern to Lab Anim. 2009;37(SUPPL.

article thumbnail

Preparing the next generation of drug discovery scientists

Drug Discovery World

This ranges from understanding disease processes and identifying possible drug targets, to organising testing, rolling out clinical trials, negotiating complex regulations and licensing and finally, treating patients. He has taught on many programmes across St George’s and co-created the Clinical Pharmacology degree from 2016.